MedTech firm Biorithm secures $3.5M in Series A funding to advance maternal care globally

Photo Credit: Freepik

Biorithm, a global women’s health MedTech has secured $3.5 million in Series A funding, co-led by Adaptive Capital Partners and SEEDS Capital, investment arm of government agency Enterprise Singapore. With a homegrown spirit and a global vision, Biorithm is dedicated to advancing pregnancy care by developing cutting-edge solutions for personalized connected maternity care.

Biorithm is committed to ending preventable pregnancy complications by pioneering new standards of care through protocol-based remote monitoring of maternal and fetal biometrics. Biorithm’s Femom is a patient-friendly technology that facilitates patient monitoring, accessible personalized guidance, and seamless integration of predictive analytics that help clinicians to identify early signs of complication.

"There is a collapse of maternal care driven by socio-economic factors and limitation of current monitoring technologies in many regions across the world, and we are hard at work to solve this problem in partnership with the wider health ecosystems at play. The investment we have received is a testament to our mission at Biorithm, and a future where every expectant mother has access to healthcare that is not only proactive but profoundly connected to her unique journey,” Amrish Nair, Founder and CEO, Biorithm.

The funding will be utilized to double down on expanding the reach of Biorithm’s connected pregnancy management solutions firstly across Southeast Asia and the United States of America (US). To bolster its expansion blueprint, Biorithm is headquartered in two locations, with its regional headquarters in Singapore as a strategic hub for Southeast Asian expansion, and with Boston as its US headquarters.

Biorithm is also channeling its incoming funding into further research that demonstrates how remote care can be most effectively deployed. Having successfully completed clinical trials with healthcare institutions in Singapore and the United Kingdom, Biorithm will be expanding its clinical trial footprint to more of its priority markets. In its aim to strengthen the overall women’s health ecosystem, Biorithm will chart out and foster key partnerships with various stakeholders globally to improve maternal and baby health through data, personalized and accessible care.

“Building a system of connected medical care is crucial to help clinicians predict, diagnose, and formulate calculated decisions on early intervention to prevent complications and devise treatments. We are excited with our investment into Biorithm as the company is focused on creating measurable and actionable value in maternal health, integrating this system across all touchpoints to ensure safety throughout the pregnancy journey.” - Shi Ying, Founder & Managing Partner, Adaptive Capital Partners.